Zurcher Kantonalbank Zurich Cantonalbank Grows Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 624.2% in the 4th quarter, HoldingsChannel reports. The firm owned 228,642 shares of the specialty pharmaceutical company’s stock after acquiring an additional 197,072 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Jazz Pharmaceuticals were worth $38,869,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. Hilltop National Bank bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $36,000. Farther Finance Advisors LLC lifted its position in Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares during the last quarter. GoalVest Advisory LLC bought a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $51,000. Danske Bank A S purchased a new stake in Jazz Pharmaceuticals in the third quarter worth approximately $40,000. Finally, Quent Capital LLC purchased a new stake in Jazz Pharmaceuticals in the third quarter worth approximately $44,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. Raymond James Financial began coverage on shares of Jazz Pharmaceuticals in a research note on Friday, April 10th. They issued an “outperform” rating and a $227.00 price objective for the company. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Needham & Company LLC lifted their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, Royal Bank Of Canada boosted their price target on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.29.

Insider Transactions at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the transaction, the senior vice president directly owned 28,728 shares of the company’s stock, valued at approximately $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,287 shares of the stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $182.94, for a total transaction of $235,443.78. Following the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 74,015 shares of company stock valued at $14,180,486. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $202.56 on Tuesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86. Jazz Pharmaceuticals PLC has a fifty-two week low of $97.50 and a fifty-two week high of $207.48. The firm has a market cap of $12.47 billion, a PE ratio of -33.93, a price-to-earnings-growth ratio of 0.35 and a beta of 0.23. The business has a 50 day moving average price of $184.27 and a 200-day moving average price of $167.51.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the firm earned $6.51 earnings per share. The firm’s revenue for the quarter was up 8.1% on a year-over-year basis. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 20.65 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.